Coherus Oncology Q3 2026 earnings

CHRS · 2026-11-09 16:20 AMC ET · 8-K on SEC

Revenue grew sequentially, but the company reported a larger net loss and a significant cash burn driven by restructuring and debt repayment.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$14.3M+23%+0.2%Ex. 99.1, income statement
EPS (GAAP)$(0.25)+34%+14%Ex. 99.1, income statement
EPS (adjusted)$(0.20)+39%+5%Ex. 99.1, income statement
Adj. EBITDA$4.1M+18%+5%Ex. 99.1, income statement
Adj. EBITDA margin29%+5 pp+1 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
LOQTORZI (net revenue)$14.3M+23%100%Driven by volume growth

Margins and costs

  • Gross margin 71% (prior 67%, change +4 pp)
  • Operating expenses $47.9M (+10% YoY)
  • One-offs in the quarter Loss on debt extinguishment $3.4M; Impairment of out-license asset $1.6M
  • Effective tax rate N/A
  • Non-GAAP bridge Adds back stock-based compensation, loss on debt extinguishment, impairment of out-license asset, change in fair value of derivative liabilities, and amortization of intangible assets

KPIs

MetricActualPrior quarterPrior yearChange
Cash, cash equivalents and marketable securities$83.6M$105.3M$172.1M-$21.7M
Net cash used in operating activities$34.0M$62.1M$46.6M-$28.1M
Headcount reduction~30%N/AN/AN/A

Guidance

MetricGuidePrior guideChange
Core cash burn$6M to $7M quarterly$30M to $35M quarterly-$24M to -$28M
LOQTORZI revenues required to cover core burn$25M to $30M quarterly$30M to $35M quarterly-$5M to -$10M

What drove it

  • Revenue story Net revenue increased 23% year-over-year and 0.2% quarter-over-quarter, driven by volume growth of LOQTORZI.
  • EPS story The EPS improvement year-over-year was driven by lower operating losses, while the sequential increase was driven by a larger net loss.
  • One-off check Loss on debt extinguishment $3.4M (Q3 2026) and impairment of out-license asset $1.6M (Q3 2026)

The good

  • LOQTORZI revenue growth of 23% YoY
  • Adj. EBITDA margin expansion of 5 pp YoY

The bad

  • Net loss widened sequentially by 16%
  • Cash burn increased by $28.1M YoY
  • Cash balance declined by $21.7M YoY

The ugly

  • none

Open questions

  • What is the specific impact of the ~30% headcount reduction on R&D and SG&A efficiency?
  • What are the terms and conditions of the 2031 Term Loan proceeds?
  • What is the timeline for the strategic prioritization plan to deliver financial self-sufficiency?
Full release

Coherus Oncology (CHRS) earnings release, November 9, 2026

Coherus Oncology, Inc. (CHRS) · Form 8-K, Item 2.02 · Filed · SEC filing

​

Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan

​ – Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development – ​ – Deprioritize development of tagmokitug/toripalimab in other indications to allocate resources toward advancing the lead indication – ​ – Right-sizing reduces headcount by ~30%, aligning organization with forward-focused needs – ​ – Reports LOQTORZI® net revenue of $14.0 million in Q3 2026 – ​ – Conference call today at 5:00 p.m. Eastern Standard Time – ​

REDWOOD CITY, Calif.,

November 9, 2026 -- Coherus Oncology, Inc.

(Nasdaq: CHRS) today reported financial results for the third quarter 2026 and provided an overview of recent business highlights.

“

The strategic prioritization of esophageal cancer as our best-in-disease focus for tagmokitug, together with the Transition Services Agreement wind-down and the toripalimab process transfer completion, provides an ideal opportunity to right-size the organization and deliver financial benefits that flow directly from this prioritization,” said Denny Lanfear, Chief Executive Officer of Coherus Oncology. “Over the next four or five quarters we will remain intensely focused on growing LOQTORZI market share in relation to chemo-only, an inferior therapeutic approach, and off-label IO, which has not demonstrated standard-of-care level of benefit for patients living with nasopharyngeal carcinoma. We believe this approach can provide a path to financial self-sufficiency.”

“Esophageal cancers constitute difficult-to-treat tumors with significant unmet medical need. The compelling anti-tumor activity observed in both ESCC and EAC tumors suggests that Tregs are a critical driver of resistance. Importantly, we saw tagmokitug enhance PD-1’s activity, demonstrate activity in PD-L1 negative tumors, and rescue PD-1 refractory patients,” said Rosh Dias, M.D., Chief Medical Officer of Coherus Oncology. “Our immediate next step is to align with the FDA on our plans to expand the signal observed in esophageal cancer, with an initial focus on the second-line setting. This represents the fastest path to market in this underserved patient population.”

​

“The financial benefits of right-sizing the organization and reducing the scope of our forward-focused efforts provide substantial and durable benefits to our operating model,” said Bryan McMichael, Chief Financial Officer of Coherus Oncology. “These benefits will be realized over the next two quarters, lowering our core cash burn by $6 million to $7 million quarterly, which in turn lowers the quarterly LOQTORZI revenues required to cover core burn to $25 million to $30 million, down from $30 million to $35 million, as previously guided.”

​

​

RECENT BUSINESS HIGHLIGHTS

​

LOQTORZI® (toripalimab-tpzi) Commercial Updates¹

​

ADVANCEMENT OF INNOVATIVE, NEXT-GENERATION

ONCOLOGY PIPELINE

​

Tagmokitug is a highly selective, cytolytic anti-CCR8 antibody designed to preferentially deplete CCR8-positive regulatory T cells (Tregs) in the tumor microenvironment, with the goal of overcoming immune resistance and enhancing antitumor immune responses. Tagmokitug is being evaluated in the TREGCHECK™ Phase 1b/2a clinical program in combination with toripalimab, with and without chemotherapy. As part of the strategic prioritization plan, Coherus will focus near-term tagmokitug development on esophageal cancer and deprioritize the other tagmokitug-toripalimab cohorts presented during our October 28, 2026, data release. The Company will continue ongoing first-line ESCC and second-line ESCC and EAC indications and pursue regulatory alignment on an expedited development path, initially focused on second-line esophageal cancer.

​

​

​

Figure 1. Second-line ESCC/EAC waterfall plot from TREGCHECK™ 102 Cohorts A (2L EAC) and B (2L ESCC). In the 700 mg dose sub-group, the Clinical Benefit Rate (CBR) was 55.6% and the confirmed Overall Response Rate (cORR) was 33.3%.

Data as of October 14, 2026

​

​

​²

Figure 2. Second-line ESCC/EAC swimmer plot from TREGCHECK™ 102 Cohorts A (2L EAC) and B (2L ESCC). Median Progression-Free Survival was 5.5 months.

Data as of October 14, 2026

​

​

Casdozokitug is a first-in-class IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line unresectable hepatocellular carcinoma (uHCC) to assess treatment benefit, safety, and response biomarkers.

​

​

THIRD QUARTER 2026 FINANCIAL RESULTS

​

Net revenue from continuing operations was $14.3 million and $11.6 million during the three months ended September 30, 2026 and 2025, respectively, and $40.9 million and $29.4 million during the nine months ended September 30, 2026 and 2025, respectively. The increases were driven primarily by volume growth of LOQTORZI.

​

Cost of goods sold (COGS) from continuing operations was $4.1 million and $3.7 million during the three months ended September 30, 2026 and 2025, respectively, and $12.1 million and $9.8 million during the nine months ended September 30, 2026 and 2025, respectively. The increases were primarily due to volume growth of LOQTORZI.

​

Research and development (R&D) expenses from continuing operations were $22.6 million and $27.3 million for the three months ended September 30, 2026 and 2025, respectively, and $65.6 million and $77.9 million during the nine months ended September 30, 2026 and 2025, respectively. The decreases were primarily due to savings from reduced headcount, lower infrastructure costs, and lower clinical trial and R&D manufacturing costs.

​

Selling, general and administrative (SG&A)... (truncated)re driven primarily by lower headcount and decreased operating costs resulting from Coherus completing the exit from the biosimilar business in 2025.

​³

Net loss from continuing operations for the third quarter of 2026 was $38.9 million, or $(0.25) per share on a diluted basis, compared to $44.5 million, or $(0.38) per share on a diluted basis, for the same period in 2025. Net loss for the nine months ended September 2026 was $109.2 million, or $(0.73) per share on a diluted basis, compared to $136.8 million, or $(1.18) per share on a diluted basis for the same period of 2025.

​

Non-GAAP net loss from continuing operations for the third quarter of 2026 was $31.2 million, or $(0.20) per share on a diluted basis, compared to $38.9 million, or $(0.33) per share for the same period in 2025. Non-GAAP net loss for the nine months ended September 2026 was $95.3 million, or $(0.64) per share on a diluted basis, compared to $118.8 million, or $(1.02) per share for the same period in 2025. See “Non-GAAP Financial Measures” below for a discussion on how Coherus calculates non-GAAP net loss from continuing operations and a reconciliation to the most directly comparable GAAP measures.

​

Cash, cash equivalents and marketable securities totaled $83.6 million as of September 30, 2026, compared to $172.1 million as of December 31, 2025. These balances were inclusive of Transition Services Agreement (TSA)-related collections that will be applied to associated TSA payables and accrued liabilities which totaled $19.6 million and $65.1 million as of September 30, 2026 and December 31, 2025, respectively.

​

Conference Call Information

When: Monday, November 9, 2026, starting at 5:00 p.m. Eastern Standard Time

To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/

BI55798b5af6004203b3a31cfe6dff187e

Webcast: https://edge.media-server.com/mmc/p/ qhta3pue

A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations

​

Please dial in 15 minutes early to ensure a timely connection to the call.

About Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting esophageal, liver, and prostate cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M nasopharyngeal carcinoma while advancing the development of its two pipeline candidates in combination with LOQTORZI, and additionally through strategic partnerships. The Company has global rights to both clinical-stage candidates and plans to execute ex-U.S. licensing deals as the clinical data support such transactions.

​

Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including gastroesophageal junction, esophageal adenocarcinoma, and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.

​

For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com

​⁴

Financial statements

Income Statement

Three Months Ended — (unaudited)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Net revenue14,27411,57140,89129,424
Costs and expenses:
Cost of goods sold4,0923,72112,1489,769
Research and development22,60627,25265,59177,914
Selling, general and administrative21,22524,93165,28376,995
Total costs and expenses47,92355,904143,022164,678
Loss from operations-33,649-44,333-102,131-135,254
Interest expense-2,781-2,325-7,290-6,752
Loss on debt extinguishment-3,363-3,363
Other income (expense), net9182,1413,6275,229
Loss from continuing operations before income taxes-38,875-44,517-109,157-136,777
Net loss from continuing operations-38,875-44,517-109,157-136,777
Net income (loss) from discontinued operations, net of tax-4598,98610,865342,444
Net income (loss)-39,334-35,531-98,292205,667
Net loss per share from continuing operations - basic and diluted-0.25-0.38-0.73-1.18
Net income (loss) per share from discontinued operations - basic and diluted$—0.080.072.95
Net income (loss) per share - basic and diluted-0.25-0.31-0.661.77
Weighted-average number of shares used in computing net income (loss) per share:
Basic and diluted154,970,687116,229,170148,796,665116,056,247

Income Statement

Three Months Ended — (unaudited)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
GAAP net loss from continuing operations-38,875-44,517-109,157-136,777
Adjustments:
Stock-based compensation expense3,6823,3228,65013,535
Loss on debt extinguishment3,3633,363
Impairment of out-license asset, net1,6461,646
Change in fair value of derivative liabilities810
Amortization of intangible assets6256521,8751,986
Non-GAAP net loss from continuing operations-31,205-38,897-95,269-118,800
GAAP
Net loss per share from continuing operations, basic and diluted-0.25-0.38-0.73-1.18
Shares used in computing basic and diluted net loss per share154,970,687116,229,170148,796,665116,056,247
Non-GAAP
Net loss per share from continuing operations, basic and diluted-0.2-0.33-0.64-1.02
Shares used in computing basic and diluted net loss per share154,970,687116,229,170148,796,665116,056,247

Balance Sheet

September 30, — (unaudited)

September 30, – 2026December 31, – 2025
Assets
Cash and cash equivalents53,48788,879
Investments in marketable securities30,14283,246
Trade receivables, net13,72017,815
Inventory14,1783,172
Intangible assets, net44,36446,239
Other assets15,21318,992
Total assets171,104258,343
Liabilities and Stockholders’ Equity
Accrued rebates, fees and reserve13,74630,397
TSA payables and accrued liabilities19,63865,065
Term loans52,55137,051
Other liabilities59,92064,816
Total stockholders' equity25,24961,014
Total liabilities and stockholders’ equity171,104258,343

Cash Flow

Three Months Ended — (unaudited)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Cash, cash equivalents and restricted cash at beginning of the period83,163217,15689,119126,250
Net cash used in operating activities-34,019-46,339-153,995-118,797
Purchases of investments in marketable securities-30,064-68,850-50,349-89,576
Proceeds from maturities of investments in marketable securities22,4551,650104,1261,650
Net cash received related to the Sale Transactions478,681
Milestone payment to Junshi Biosciences-12,500
Other investing activities, net-27-1,100-330
Net cash (used in) provided by investing activities-7,609-67,22752,677377,925
Proceeds from 2031 Term Loan, net of discount and issuance costs52,65752,657
Proceeds from issuance of common stock under Public Offering, net of issuance costs53,650
Partial repayment of Revenue Purchase and Sale Agreement-47,652
Proceeds from purchases under the employee stock purchase plan202188
Repayment and redemption of 2026 Convertible Notes, including transaction costs-121-233,185
Repayment of 2029 Term Loan, including premiums and fees-40,661-40,661
Other financing activities, net50253-1,137
Net cash provided by (used in) financing activities12,046265,780-281,786
Net decrease in cash, cash equivalents and restricted cash-29,582-113,564-35,538-22,658
Cash, cash equivalents and restricted cash at end of the period53,581103,59253,581103,592

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, the ability of Coherus’ innovative oncology pipeline to enhance outcomes for cancer patients; the timing and results of anticipated clinical data results; Coherus’ ability to maintain and grow revenues; the effectiveness of Coherus’ cost reduction plan; and Coherus’ expectations about total addressable opportunity for LOQTORZI and for each of its product candidates.

​... (truncated)risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2026 filed with the Securities and Exchange Commission on or about the date of this press release, including the section therein captioned “Risk Factors” and in other documents Coherus files with the Securities and Exchange Commission. Coherus’ results for the fiscal quarter ended September 30, 2026 are not necessarily indicative of its operating results for any future periods.

​

LOQTORZI

®, whether or not appearing in large print or with the trademark symbol, is a registered trademark of Coherus Oncology, Inc.

​

©2026 Coherus Oncology, Inc. All rights reserved.

​

Coherus Contact Information:

For Investors & Media:

Carrie Graham

Vice President, Investor Relations and Advocacy

IR@coherus.com

​⁵

Coherus Oncology, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

​

​

​

​⁶

Coherus Oncology, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

​

​

​

​⁷

Coherus Oncology, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

​

​

​

​⁸

Non-GAAP Financial Measures

To supplement the financial results presented in accordance with GAAP, Coherus has included in this press release non-GAAP net loss from continuing operations, and the related per share measures, which exclude from net loss from continuing operations and the related per share measures, stock-based compensation expense, amortization and impairments of intangible assets, loss on debt extinguishment, and change in fair value of our derivative liabilities. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than similar non-GAAP financial information disclosed by other companies. Coherus encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations set forth below, to more fully understand Coherus’ business.

Coherus believes that the presentation of these non-GAAP financial measures provides useful supplemental information to, and facilitates additional analysis by, investors. In particular, Coherus believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare Coherus’ results from period to period, and to identify operating trends in Coherus’ business. Coherus also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.

Coherus

Oncology, Inc.

Reconciliation of GAAP Net Loss from Continuing Operations to Non-GAAP Net Loss from Continuing Operations

(in thousands, except share and per share data)

(unaudited)

​

​⁹

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.